Madison Clarke
Hepatitis A is a vaccine-preventable virus that is transmitted through the faecal-oral route. The hepatitis A vaccine was first approved in the European Union in 1991 and the United States in 1995. Since universal childhood vaccination was recommended in 2006, hepatitis A cases in the U.S. have dropped by 95%. Hepatitis A vaccination is recommended for all children over one year of age, people with chronic liver disease, and those travelling to regions where the virus is prevalent. The vaccine is highly effective, with an efficacy rate of around 95% and long-lasting protection of at least twenty years.
| Characteristics | Values |
|---|---|
| First approved | 1991 (European Union), 1992 (worldwide), 1995 (United States) |
| First licensed | 1992, 1995 |
| First licensed as a 2-dose vaccine for children | 1995 |
| Minimum age for which the vaccine was licensed | Lowered to 12 months in 2005 |
| Percentage of cases reduced by | 95% |
| Effectiveness | 95% |
| Duration of protection | 20 years, possibly a lifetime |
| Number of doses | 2 |
| Time between doses | 6 months |
Explore related products
What You'll Learn
Hepatitis A vaccine was first approved in the EU in 1991 and the US in 1995
Hepatitis A is a vaccine-preventable virus that is transmitted through the faecal-oral route. It is caused by the hepatitis A virus (HAV) and is primarily transmitted when the virus leaves the body in stool and enters another person's body when it is accidentally swallowed. Hepatitis A is the most common vaccine-preventable virus acquired during travel, so people travelling to places where the virus is common, like the Indian subcontinent, Africa, Central America, South America, Asia, and Eastern Europe, should be vaccinated.
The Hepatitis A vaccine was first approved in the European Union in 1991 and in the United States in 1995. The vaccine is given in two doses, six months apart, and provides long-term protection against hepatitis A virus (HAV) infection. The World Health Organization (WHO) recommends universal vaccination in areas where the disease is moderately common. The vaccine is on the WHO's List of Essential Medicines.
The Hepatitis A vaccine is highly effective, with an efficacy rate of around 95%. It lasts for at least twenty years and possibly a person's entire life. The vaccine is safe and is given by injection into a muscle. Most Hepatitis A vaccines contain inactivated viruses, while a few contain weakened viruses. The inactivated vaccine is safe, but more evidence is needed to assess the safety of the attenuated vaccine.
The development and approval of the Hepatitis A vaccine have played a significant role in reducing the incidence of hepatitis A cases worldwide. Since universal childhood vaccination was recommended in 2006, hepatitis A cases in the United States dropped by 95%. The strategy for Hepatitis A vaccination varies across different countries and mainly includes vaccination among high-risk populations, regional childhood vaccination, and universal childhood vaccination.
Chickenpox Vaccine: What's Its Name?
You may want to see also
Explore related products
The vaccine is 95% effective and lasts for at least 20 years
Hepatitis A vaccines are highly effective in preventing Hepatitis A Virus (HAV) infection. The vaccine is given in two doses, six months apart, and protection begins approximately two to four weeks after the initial vaccination. The first dose should be administered at 12–23 months old, and the second dose at 2–4 years old. The hepatitis A vaccine is recommended for all children over one year of age, and unvaccinated children and adolescents aged 2–18 years. The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for children aged 12–23 months.
The hepatitis A vaccine is effective in around 95% of cases and lasts for at least 20 years, and possibly a person's entire life. Inactivated hepatitis A vaccines offer significant protection for at least two years, and attenuated vaccines offer protection for at least five years. According to Immunize.org, the hepatitis A vaccine might last at least 25 years for adults and about 14–20 years for children. A 2020 review of research suggests that two doses of the hepatitis A vaccine may protect for 30–40 years or even provide lifetime protection. The exact duration of protection is unknown, but studies have shown that anti-HAV antibodies persist for at least 20 years in people who received a complete vaccine series.
The hepatitis A vaccine was first approved in the European Union in 1991 and in the United States in 1995. Since universal childhood vaccination was recommended in 2006, hepatitis A cases in the U.S. dropped by 95%. The vaccine was phased in around 1996 for children living in high-risk areas. From 1996, when the HepA vaccine was introduced, through 2011, hepatitis A cases decreased by over 95%. However, there was a re-emergence of the disease in 2016 due to outbreaks among people reporting drug use and homelessness.
The hepatitis A vaccine is safe, and severe side effects are very rare. Pain at the injection site occurs in about 15% of children and half of adults. Most vaccines contain inactivated viruses, while a few contain weakened viruses. The vaccines with weakened viruses are not recommended during pregnancy or for those with poor immune function. Soreness or redness at the injection site, fever, headache, tiredness, or loss of appetite can occur after receiving the vaccine.
Foreign Smoking Cessation Vaccines: Do They Exist?
You may want to see also
Explore related products
It is recommended for travellers to high-risk areas
Hepatitis A is a significant global public health issue. The Hepatitis A vaccine (HepA) was first licensed for use in the United States in 1995, although some sources state it was first licensed in 1992. The vaccine was phased in around 1996, initially for children living in high-risk areas. Since universal childhood vaccination was recommended in 2006, hepatitis A cases in the U.S. dropped by 95%.
The vaccine is recommended for travellers to high-risk areas. Hepatitis A is the most common vaccine-preventable virus acquired during travel. It is recommended that people travelling to places where the virus is common, such as the Indian subcontinent, Africa, Central and South America, Asia, and Eastern Europe, should be vaccinated. The vaccine is also recommended for persons over six months of age travelling to or working in countries with high or intermediate endemicity of HAV infection.
The vaccine is given in two doses, with the initial dose followed by a booster six to twelve months later. The first dose of the vaccine provides protection for approximately two to four weeks. The second dose is given six months later, and this provides long-term protection. The vaccine is highly effective, with an efficacy rate of around 95%. It is safe and offers protection for at least twenty years, and possibly a person's entire life.
The Hepatitis A vaccine is an important preventative measure for travellers to high-risk areas, providing long-lasting protection against the virus. It is recommended that travellers to these areas get vaccinated to reduce the risk of infection.
Vaccine Coverage: Does Your Insurance Plan Measure Up?
You may want to see also
Explore related products
It is given in two doses, six months apart
Hepatitis A vaccines were first licensed for use in the United States in 1995, although sources suggest it was first licensed in 1992. The vaccine was phased in around 1996, initially for children living in high-risk areas. The hepatitis A vaccine is highly effective, protecting against the hepatitis A virus (HAV) in around 95% of cases. It is also long-lasting, providing immunity for at least 20 years, and possibly a lifetime.
The hepatitis A vaccine is typically given in two doses, six months apart. The first dose should be followed by a booster six to twelve months later. This two-dose schedule is recommended for children over the age of one, and it provides long-term protection. The interval between the two doses can be extended without adversely affecting immunogenicity. The vaccine is administered by injection into the muscle of the upper arm.
In certain cases, a single dose of the hepatitis A vaccine may be sufficient. For example, for travellers who have already received a partial vaccination, a single dose may be administered before travel, according to the vaccine schedule. Similarly, infants aged 6 to 11 months travelling outside the United States may receive a single travel-related dose, which does not count towards the routine two-dose series.
The hepatitis A vaccine has significantly reduced the incidence of hepatitis A. From 1996, when the vaccine was introduced, through 2011, hepatitis A cases in the United States decreased by over 95%. However, outbreaks still occur, particularly among high-risk populations, including those experiencing homelessness and drug use.
Hep B Vaccine: Number of Shots Required
You may want to see also
Explore related products
It is safe for children over one year old
Hepatitis A vaccines have been available for almost two decades and are generally considered safe and effective for children over one year old. The vaccines are given in two doses, six months apart, and offer protection for at least twenty years, and possibly a lifetime. The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for children aged 12-23 months and catch-up vaccination for children aged 2-18 years who have not previously been vaccinated.
The hepatitis A vaccine is safe for children over one year old, with mild and short-lived side effects such as soreness, redness, fever, headache, tiredness, and loss of appetite. These side effects occur in about 15% of children and half of adults. While rare, severe allergic reactions can occur, and medical advice should be sought if symptoms such as swelling or redness of the face or hives appear.
The hepatitis A vaccine is recommended for children over one year old, especially those travelling to or living in areas with high or intermediate endemicity of HAV infection. Vaccination is also advised for children with a higher risk of infection, such as those with chronic liver disease or HIV infection, or those in close contact with someone infected. In the United States, hepatitis A was the most frequently reported type of hepatitis before 2004. However, from 1996, when the HepA vaccine was introduced, through 2011, hepatitis A cases decreased by over 95%.
The hepatitis A vaccine is highly effective in preventing HAV infection, and scientific evidence supports its safety. The vaccine contains a small piece of the hepatitis A virus that has been killed or inactivated, so it cannot cause hepatitis A infections. After vaccination, the body's immune system produces antibodies that provide long-term protection against the virus. This immunity helps prevent the spread of infections and protects others, including babies too young for the vaccine and those with serious illnesses.
Smallpox Vaccination: The US History and End Date
You may want to see also
Frequently asked questions
The Hepatitis A vaccine was first licensed in 1992. However, it was first licensed for use in the United States in 1995.
The Hepatitis A vaccine is effective in around 95% of cases and provides long-term protection against the Hepatitis A virus.
The US Centers for Disease Control and Prevention (CDC) recommends vaccination of all children over one year of age, people with chronic liver disease, and people travelling to places where the virus is common.
